Fredrick Jarskog, MD

Long-term Improvements in Site-Rated Outcomes With Deutetrabenazine Treatment in Patients With Tardive Dyskinesia

Background: Tardive dyskinesia (TD) is a movement disorder that may intensify the stigma of patients with psychiatric disorders. In the ARM-TD and AIM-TD trials (parent studies), deutetra...

Nicholas Gross , MS;

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Joseph McEvoy , MD;

Fredrick Jarskog , MD;

Karen Anderson , MD;

Stanislaw Ochudlo , MD, PhD;

Hubert Fernandez , MD;

03/01/2019

Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrab...

Hubert Fernandez , MD;

Stewart Factor , DO;

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

William Ondo , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Karen Anderson , MD;

03/01/2019

Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study

Background: Deutetrabenazine was efficacious and safe in treating tardive dyskinesia (TD) in the 12-week ARM-TD and AIM-TD studies. Objective: To evaluate the long-term safety and tolerab...

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Karen Anderson , MD;

William Ondo , MD;

Hubert Fernandez , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Stewart Factor , DO;

03/01/2019

Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities

Background: Tardive dyskinesia (TD) is managed by dose reduction or interruption of dopamine-receptor antagonists (DRAs), possibly causing psychiatric disorder relapse. Deutetrabenazine (...

Mat Davis , PhD;

David Stamler , MD;

Robert G. Hauser , MD, MBA, PhD;

Joohi Jimenez-Shahed , MD;

Fredrick Jarskog , MD;

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Karen Anderson , MD;

Joseph McEvoy , MD;

Hubert Fernandez , MD;

Stanislaw Ochudlo , MD, PhD;

03/01/2019